Clinical trial Recruiting at 1 site Phase2; Phase3 Interventional Ages 15 to 18

Transplanting insulin-producing stem cells for treating Type 1 Diabetes

Official title: Autologous Insulin Producing Mesenchymal Stem Cell Transplantation in Youth With Type 1 Diabetes

Run by Ain Shams University · NCT06951074 · Data updated 2026-11-12

This study is testing whether transplanting insulin-producing stem cells from fat can help people with Type 1 Diabetes better control their blood sugar levels.

Quick facts

PhasePhase2; Phase3
Study typeInterventional
Ages15 Years to 18 Years
SexAll
Enrollment20 (estimated)
SponsorAin Shams University
Academic / other
Locations1 site (Cairo)
StatusRecruiting
StartedApril 1, 2025
Main results expectedMay 1, 2026
Study endsSeptember 1, 2026
Registry record updatedApril 30, 2025
Trial IDNCT06951074 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are individuals diagnosed with Type 1 Diabetes who do not have other autoimmune diseases or chronic conditions.

Probably not a fit

Patients with other autoimmune diseases or those experiencing micro or macro vascular complications may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial investigates the use of autologous insulin-producing mesenchymal stem cells derived from adipose tissue to treat patients with Type 1 Diabetes. The study aims to differentiate these stem cells into insulin-producing cells and assess their ability to regulate blood sugar levels post-transplant. By utilizing a multistep differentiation technique, the researchers hope to restore pancreatic function and improve glycemic control in participants. The trial will evaluate both in vitro and in vivo insulin production following the infusion of these stem cells.

Why it matters

Potential benefit: If successful, this approach could significantly improve glycemic control and reduce the dependency on insulin therapy for patients with Type 1 Diabetes.

How similar studies have gone: Other studies have shown promise in using stem cell therapies for Type 1 Diabetes, but this specific approach using adipose-derived mesenchymal stem cells is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Type 1 diabetes

Exclusion Criteria:

* patients with other autoimmune diseases
* patients with micro or macro vascular complications
* patients with other chronic diseases

Where it's running

  • Children Hospital Eldemerdash
    Cairo, Egypt
    Recruiting

Study contacts

  • Principal investigator: Rasha S Elmetwally, A. Prof — Assistant professor of Pediatrics, Faculty of Medicine, Ain Shams University
  • Study coordinator: Rasha S Elmetwally, MD
  • Email: dr.rashaeladawy@med.asu.edu.eg
  • Phone: 20201092143033

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.